Similar articles

• Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?

  Morris AJ, Howden CW, Robertson C, Duncan A, Torley H, Sturrock RD, Russell RI. Morris AJ, et al. Gut. 1991 Dec;32(12):1470-2. doi: 10.1136/gut.32.12.1470. Gut. 1991. PMID: 1773950 Free PMC article. Clinical Trial.
• [Determination of endotoxin in inflammatory rheumatic diseases--the effect of nonsteroidal anti-inflammatory agents on intestinal permeability].

  Busch J, Hammer M, Brunkhorst R, Wagener P. Busch J, et al. Z Rheumatol. 1988 May-Jun;47(3):156-60. Z Rheumatol. 1988. PMID: 3213262 German.
• Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease.

  Mielants H, De Vos M, Goemaere S, Schelstraete K, Cuvelier C, Goethals K, Maertens M, Ackerman C, Veys EM. Mielants H, et al. J Rheumatol. 1991 Mar;18(3):394-400. J Rheumatol. 1991. PMID: 1906939
• [Ankylosing spondylitis and phosphocalcic parameters].

  Wendling D, Dumoulin G. Wendling D, et al. Rev Rhum Mal Osteoartic. 1991 Apr;58(4):279-81. Rev Rhum Mal Osteoartic. 1991. PMID: 2057717 Review. French. No abstract available.
• Managing seronegative spondarthritides.

  Koehler L, Kuipers JG, Zeidler H. Koehler L, et al. Rheumatology (Oxford). 2000 Apr;39(4):360-8. doi: 10.1093/rheumatology/39.4.360. Rheumatology (Oxford). 2000. PMID: 10817767 Review. No abstract available.